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Background: Different molecular subtypes of breast cancer have been identified based on gene expression
profiling. Treatment suggestions based on an approximation of these subtypes by immunohistochemical criteria
have been published by the St Gallen international expert consensus panel. Ductal carcinoma in situ (DCIS) can be
classified into the same molecular subtypes. Our aim was to study the relation between these newly defined
subtypes and prognosis in DCIS.
Methods: TMA including 458 women from a population-based cohort with DCIS diagnosed 1986–2004 was used.
Stainings for ER, PR, HER2 and Ki67 were used to classify the surrogate molecular subtypes according to the St Gallen
criteria from 2011. The associations with prognosis were examined using Kaplan-Meier analyses and Cox proportional
hazards regression models.
Results: Surrogate molecular subtyping could be done in 381 cases. Mean follow up was 164 months. Of the classified
DCIS 186 were Luminal A (48.8%), 33 Luminal B/HER2- (8.7%), 74 Luminal B/HER2+ (17.4%), 61 HER2+/ER- (16.0%) and
27 Triple Negative (7.1%). One hundred and two women had a local recurrence of which 58 were invasive. Twenty-two
women had generalised disease, 8 without a prior local recurrence. We could not find a prognostic significance of the
molecular subtypes other than a higher risk of developing breast cancer after more than 10 years of follow-up among
women with a Triple Negative DCIS (OR 3.2; 95% CI 1.1-9.8).
Conclusions: The results from this large population-based cohort, with long-term follow up failed to demonstrate a
prognostic value for the surrogate molecular subtyping of DCIS using the St Gallen criteria up to ten years after
diagnosis. More than ten years after diagnosis Triple Negative DCIS had an elevated risk of recurrence.Background
At the 12th St Gallen International Breast Cancer
Conference 2011 a new classification system of biological
breast cancer subtypes was adopted (Goldhirsch, [1]). The
intrinsic molecular subtypes based on gene expression
analyses (Perou [2], Sorlie [3]) are for practical purposes
approximated using clinicopathological criteria. Systemic
therapy recommendations for invasive breast cancer ac-
cording to the subtype classification were also proposed.
The surrogate pathology-based definitions were slightly
changed at the last St Gallen conference (Goldhirsch, [4]).* Correspondence: wenjing.zh@gmail.com
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reproduction in any medium, provided the orDuctal carcinoma in situ (DCIS) can be classified into
the same molecular subtypes as invasive breast cancer
by gene expression analysis [5,6]. Immunohistochemistry
(IHC) has also been used for DCIS by Livasy et al. (Livasy)
to mimic the molecular subtypes. However, the new
St Gallen classification has not been applied on DCIS be-
fore. The main difference between the system used by
Livasy and the St Gallen criteria is the inclusion of prolif-
eration to the classification, measured by Ki67.
A clinically useful histopathological classification sys-
tem for DCIS predicting prognosis is still missing. Survival
is excellent after a primary diagnosis of DCIS, but the risk
of recurrence is considerably high (EBCTCG [7]). Hence,
identification of biomarkers to aid in individualized treat-
ment decisions regarding surgery and radiotherapy wouldtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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markers including Ki67 and found that biomarkers were
better than histopathological criteria for identifying risk
groups for subsequent invasive cancer and Solin et al., [9]
used a 21-gene array to identify risk groups after breast
conserving surgery (BCS) without postoperative radi-
ation. We have in an earlier paper shown that basal
like DCIS according to the classification by Livasy et al.,
had a higher but not statistically significantly higher risk
of recurrence [10].
In this study, our aim was to classify DCIS into the
same surrogate molecular subtypes proposed by the
St Gallen international expert consensus for invasive
breast cancer but also to study if there was a relation
between these surrogate molecular subtypes and prog-
nosis in DCIS.
Methods
Patients
All women, diagnosed with a primary DCIS between
1986 and 2004 in Uppland and Västmanland, Sweden
were included (n = 458). Follow-up was complete up to
November 31st, 2011.
We used three primary end points; 1) “Local recur-
rence” - including all ipsilateral events (in situ and inva-
sive), 2) “Invasive or general recurrence” - including all
invasive ipsilateral events, all regional and distant meta-
static events and finally 3) “All events” – including all ip-
silateral events, all regional and distant metastatic events
and all contralateral events. All women with an invasive
ipsilateral recurrence were accordingly included as cases
using both endpoint 1, 2 and 3. We did not include
events occurring earlier than three months after primary
diagnosis. Follow-up was divided into the first ten years
and then after ten years.
IHC and silver-enhanced in situ hybridization (SISH)
Tumour biopsies from paraffin blocks were used to con-
struct tissue microarrays (TMA). IHC for estrogen recep-
tor (ER), progesterone receptor (PR), human epidermal
growth factor receptor 2 (HER2) and Ki67 have been per-
formed as earlier desciribed (Zhou, Wärnberg [11]). For
HER2, SISH have also been performed previously (Zhou,
Wärnberg [11]).
For analysis of ER and PR, tumours with at least 1% of
cell nuclei stained were considered positive, regardless of
staining intensity [12]. We did all analyses with a cut of
at ≥10% as well, as this is the cut off still used in
Sweden. Proliferation was considered high if IHC stain-
ing for Ki67 was seen in more than 14% of tumour nu-
clei. We also used other cut offs for Ki67 (10% and 20%)
in separate analyses. In 101 of the DCIS cases where
Ki67 information was missing from the TMAs, we used
an earlier scoring of Ki67 from original slides (Wärnberg[13]). However, the earlier grouping was only made into
four different intervals; 0%, 1-10%, 11-30% and >30%
and hence, we could not include all these cases using
the 14% and 20% cut offs.
For HER2 gene amplification the American Society
of Clinical Oncology/College of American Pathologists
guideline and Australian HER2 Advisory Board criteria
for single HER2 probe testing was used (diploid, 1 to 2.5
copies/nucleus; polysomy >2.5 to 4 copies/nucleus; equivo-
cal, >4 to 6 copies/nucleus; low-level amplification, >6
to 10 copies/nucleus; and high-level amplification >10
copies/nucleus) and for dual HER2/CHR17 probe testing
(nonamplified ratio <1.8; equivocal ratio, 1.8 to 2.2; gene
amplification, >2.2). The status of HER2 expression was
relying on SISH. For those cases on which SISH was miss-
ing we considered HER2 positive if the IHC score was 3+
using the HerceptTest™.
Surrogate molecular subtypes
The different subtypes were defined and denoted by us
as follows;
 Luminal A (ER and/or PR positive, HER2 negative
and Ki67 <14%)
 Luminal B/HER2- (ER and/or PR positive, HER2
negative and Ki67 ≥14%),
 Luminal B/HER2+ (ER and/or PR positive, HER2
positive),
 HER2+/ER- (non luminal) (ER and PR negative and
HER2 positive),
 Triple Negative (ductal), (ER, PR and HER2
negative).
The surrogate definitions were based on the 2011 St
Gallen guidelines (Goldhirsch, [1]).
Cases with missing IHC data, due to lack of tumour
tissue in the TMAs, were defined as unclassified. These
cases were excluded from the survival analyses.
Statistical analyses
Baseline characteristics among patients with different
molecular subtypes were compared by Chi-square for
categorical variables or analysis of variance for continuous
variables. Survival and probabilities of local recurrence
and invasive or general disease among patients with dif-
ferent molecular subtypes were first compared by the
Kaplan-Meier method. Cox proportional hazards regres-
sion models were used to calculate hazard ratios (HRs)
with 95% confidence intervals (CIs), with adjustment for
type of surgery and postoperative radiotherapy in the
multivariate analysis. Data were analyzed using the SAS
(SAS Institute, Cary, NC) software.
This study was approved by the Ethics Committee at
Uppsala University Hospital (Dnr 2005: 118).
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Three hundred and eighty-one of the 458 DCIS cases
could be classified into the surrogate molecular subtypes
using 1% and 14% as cut offs for hormonal receptor
status and proliferation, respectively. Of the classified
women 186 were Luminal A (40.6%), 33 Luminal B/HER2-
(7.2%), 74 Luminal B/HER2+ (16.2%), 61 HER2+/ER-
(13.3%) and 27 Triple Negative (5.9%) (Table 1). This
leaves 77 (16.8%) unclassified due to missing IHC data for
one or more of the biomarkers needed. When using the
cut off ≥10% for the hormone receptor status the corre-
sponding numbers were; 184 Luminal A (47.9%), 30
Luminal B/HER2- (7.8%), 64 Luminal B/HER2+ (16.7%),
71 HER2+/ER- (18.5%) and 35 Triple Negative (9.1%) and
74 unclassified (16.2%).
Baseline characteristics of the 458 DCIS are pre-
sented in Table 1. The HER2+/ER-, Luminal B/HER2+,
HER2+/ER- and Triple Negative subtypes were more often
grade 3 compared to Luminal A and Luminal B/HER2- tu-
mours. Only 22.6% of Luminal A tumours were grade 3.
Type of surgery, mastectomy or BCS and postoperative
radiotherapy were decided according to local traditions.
About 45% of women undergoing BCS received post-
operative radiotherapy. No woman received endocrine
or chemotherapy after primary surgery. Mean follow up
was 164 months (range 3–293). Fifteen women died from
breast cancer and another 96 died from other causes. One
hundred and two women had an ipsilateral local recur-
rence of which 52 were invasive and 50 had a new DCIS.
Six of the 50 ipsilateral in situ recurrences had first an in
situ recurrence and then followed by a later ipsilateral in-
vasive local recurrence. The six in situ events followed by
an invasive event were regarded as “Local recurrences” at
the time of the in situ event, and as “Invasive or general
recurrences” at the time of the subsequent invasive event.
Twenty-two women had generalized disease, 8 of those
with no prior local recurrence. Mean follow-up to an inva-
sive local recurrence was 95.1 months (range 4–280) and
to an in situ recurrence 53.3 months (10–244). Forty-five
women had a contralateral breast cancer. Eleven of these
were secondary to an ipsilateral event. Six of the 45
had a contralateral invasive cancer and then developed
generalized disease. These six women were censored at
the time of the contralateral cancer event in the survival
analyses for “Local recurrence” and “Invasive or general
recurrence”.
With the Luminal A subtype as reference, Cox regres-
sion analyses showed no statistically significant differ-
ences between subtypes regarding “Local recurrence” or
“Invasive or general recurrence” (Table 2). However, all
subtypes showed a non-significantly higher risk of “Local
recurrence” compared to Luminal A during the first ten
years after diagnosis and treatment. We also looked at
“Local recurrence” risk after ten years of follow-up. Evenif the numbers were small and no statistically significant
differences were seen, notably the HER2+/ER- subtype
had the highest risk during the first ten years and the
lowest risk after ten years, compared with the other sur-
rogate molecular subtypes (HR 1.77, CI 95%; 0.85-3.68
and HR 0.58; 0.06-5.89). Compared to the highest risk of
“Local recurrence” for the HER2+/ER- subtype during
the first ten years the risk for an “Invasive or general recur-
rence” was the lowest (HR 0.98 CI 95%; 0.31-3.17) com-
pared to the reference subtype Luminal A. The Luminal B/
HER2-, Luminal B/HER2+ and Triple Negative subtypes
had about twice as high risk, but this was not statistically
significant. Looking at “All events” we could not find any
statistically significant differences between the surrogate
molecular subtypes during the first ten years of follow-up.
After ten years however, the risk of any event was lower,
but not statistically significant lower, in the Luminal B/
HER2+ and HER2+/ER- subtypes (HR 0.39, CI 95%; 0.11-
1.45 and HR 0.20; 0.03-1.58 respectively) while the risk
was statistically significantly higher in the Triple Negative
subtype (HR 3.21, 95% CI; 1.05-9.83). All analyses
were done for all women and for all women treated with
BCS separately and as results looked similar data are not
shown.
The Kaplan-Meier survival analyses are presented in
Figures 1 and 2. Data are shown for all women with a
primary DCIS and separately for those women undergo-
ing BCS. Graphs are presented for a) “Local recurrence”,
b) “Invasive or general recurrence” and c) “All events”.
We could not see any statistically significant differences
between the surrogate molecular subtypes in any of the
analyses.
All results were similar when using the different cut-
offs for Ki67 (10%, 14% and 20%) (data not shown). All
analyses were also done with the cut off ≥10% for ER
positivity. Results were not substantially different and data
are not shown. We performed separate analyses stratified
by post-operative radiotherapy in women undergoing BCS
with similar results (data not shown).
Discussion
In this large population-based cohort of DCIS with almost
14 years of follow-up we classified the tumours as pro-
posed by the St Gallen international expert consensus
panel for invasive breast cancer, 2011 (Goldhirsch). Des-
pite more than 100 local recurrences and almost 70 inva-
sive events we found very sparse prognostic information
using the intrinsic surrogate molecular subtype classifica-
tion. Based on few events, we found a higher risk for “All
events” for the Triple Negative subtype after ten years
of follow-up. Interestingly, the HER2+/ER- subtype was
associated with a higher risk of local recurrence but a
lower risk for invasive recurrence compared with the two
Luminal B subtypes and Triple Negative tumours.
Table 1 Characteristics of DCIS by surrogate molecular subtypes according to the St Gallen international expert consensus 2011 (n=458)
Ductal carcinoma in situ characteristics All Luminal A Luminal B/HER2- Luminal B/HER2+ HER2+/ER- Triple negative Unclassified P valueb P valuec
n=458 n=186, (%) n=33, (%) n=74, (%) n=61, (%) n=27, (%) n=77, (%)
Percentage of all n=458 (40.6) (7.2) (16.2) (13.3) (5.9) (16.8)
Percentage of all classified n=381 (48.8) (8.7) (19.4) (16.0) (7.1) -
Age mean, years 58.2 59.6 55.2 55.2 58.4 59.2 58.2
< 50 121(26.4) 48 (25.8) 12 (36.4) 23 (31.1) 14 (23.0) 8 (29.6) 16 (20.8) 0.38 0.42
50- 65 198 (43.2) 77 (41.4) 14 (42.4) 33 (44.6) 30 (49.2) 7 (25.9) 37 (48.0)
> 65 139 (30.3) 61 (32.8) 7 (21.2) 18 (24.3) 17 (27.9) 12 (44.4) 24 (31.2)
Detection mode
Screening 345 (75.5) 134 (72.0) 27 (81.8) 67 (90.5) 44 (72.1) 18 (66.7) 55 (71.4) 0.10 0.16
Clinically 112 (24.5) 51 (27.4) 6 (18.2) 7 (9.5) 17 (27.9) 9 (33.3) 22 (28.6)
Tumor size
Unifocal, mean, mm 16.7 14.9 16.5 16.4 21.8 19.9 16.3 0.93d 0.91d
Multifocal (number) n=54 n=22 n=3 n=11 n=8 n=3 n=7
Histopathological gradea
Grade 1 37 (8.1) 23 (12.4) 1 (3.0) 1 (1.4) 1 (1.6) 1 (3.7) 10 (13.0) <0.01 <0.01
Grade 2 203 (44.6) 121 (65.0) 17 (51.5) 20 (27.0) 6 (9.8) 9 (33.3) 32 (41.6)
Grade 3 215 (47.3) 42 (22.6) 15 (45.5) 53 (71.6) 54 (88.5) 17 (63.0) 35 (44.4)
Type of surgery
Breast Conserving Surgery 359 (78.4) 151 (81.2) 28 (84.8) 57 (77.0) 41 (67.2) 22 (81.5) 60 (77.9) 0.17 0.27
Mastectomy 99 (21.6) 35 (18.8) 5 (15.2) 17 (23.0) 20 (32.8) 5 (18.5) 17 (22.1)
Postoperative radiotherapy
Yes 161 (35.2) 63 (33.9) 17 (51.5) 27 (36.5) 23 (37.7) 9 (33.3) 22 (28.6) 0.42 0.33
No 297 (64.8) 123 (66.1) 16 (48.5) 47 (63.5) 38 (62.3) 18 (66.7) 55 (71.4)
aDCIS were classified according to the European Organization for Research and Treatment of Cancer (EORTC) system.
bP-values were calculated between molecular subgroups by IHC, unclassified lesions were excluded.
cP-values were calculated between molecular subgroups by IHC, unclassified lesions were included.
dChi-square test of categorical size groups (unifocal vs. multifocal).
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Table 2 Cox regression analyses of survival among surrogate molecular subtypes by immunohistochemistry in primary
DCIS (n=458), by follow-up period
Follow-up period
> 3 months – 10 years > 10 years
Type of event Unadjusted HR (95% CI) Adjusted* HR (95% CI) Unadjusted HR (95% CI) Adjusted* HR (95% CI)
Local recurrence (in situ or invasive) No. of events: 84 No. of events: 17
Luminial A 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Luminal B/HER2- 1.39 (0.64-3.01) 1.61 (0.73-3.54) no events -
Luminal B/HER2+ 1.31 (0.72-2.40) 1.63 (0.84-3.17) 0.78 (0.21-2.89) 1.01 (0.22-4.62)
HER2+/ER- 1.21 (0.62-2.34) 1.77 (0.85-3.68) 0.27 (0.03-2.14) 0.58 (0.06-5.89)
Triple negative 1.37 (0.57-3.28) 1.38 (0.56-3.38) 0.94 (0.12-7.44) 0.78 (0.09-7.22)
Unclassified 0.73 (0.36-1.49) 0.77 (0.38-1.58) 0.95 (0.25-3.60) 1.19 (0.29-4.78)
Invasive or general recurrence No. of events: 47 No. of events: 19
Luminial A 1.0 1.0 1.0 1.0
Luminal B/HER2- 2.02 (0.80-5.13) 2.51 (0.97-6.49) no events -
Luminal B/HER2+ 1.49 (0.68-3.25) 1.97 (0.83-4.67) 0.78 (0.25-2.44) 0.72 (0.21-2.56)
HER2+/ER- 0.71 (0.24-2.12) 0.98 (0.31-3.17) no events -
Triple negative 2.24 (0.83-6.06) 1.99 (0.70-5.63) 0.82 (0.11-6.35) 0.63 (0.07-5.48)
Unclassified 0.70 (0.26-1.90) 0.84 (0.31-2.33) 0.54 (0.12-2.42) 0.53 (0.12-2.42)
All events No. of events: 112 No. of events: 28
Luminial A 1.0 1.0 1.0 1.0
Luminal B/HER2- 1.24 (0.62-2.46) 1.47 (0.73-2.94) no events -
Luminal B/HER2+ 1.20 (0.71-2.01) 1.53 (0.87-2.71) 0.40 (0.12-1.37) 0.39 (0.11-1.45)
HER2+/ER- 0.92 (0.49-1.70) 1.28 (0.65-2.52) 0.17 (0.02-1.25) 0.20 (0.03-1.58)
Triple negative 1.30 (0.61-2.75) 1.37 (0.64-2.98) 2.95 (1.07-8.16) 3.21 (1.05-9.83)
Unclassified 0.78 (0.43-1.39) 0.82 (0.45-1.48) 0.85 (0.28-2.58) 1.02 (0.33-3.21)
*Adjusted for age, mode of detection, size, grade, surgery and radiotherapy.
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were based on information from the DCIS tumours.
During this period IHC was not routinely performed on
pure DCIS cases. ER, PR and HER2 status was not avail-
able and molecular subtypes were not taken into consid-
eration. When studying prognosis for the different
subtypes in this study, we adjusted for the type of sur-
gery and for post-operative radiotherapy as this is known
to effect recurrence risk.
There is no clinically established classification of DCIS
that helps us predicting the prognosis for an individual
woman. The most common grading system used today
is nuclear grade. High grade and large size has been
shown to be of some prognostic relevance for local re-
currence (EBCTCG) but we lack factors that predict risk
for developing invasive cancer. In invasive cancer, mo-
lecular subtype has been shown to predict prognosis
(Su [14], Normanno [15]) but very little data has been
published regarding DCIS [10,16]. There are no publica-
tions using the proposed criteria from St Gallen, 2011
(Goldhirsch, [1]) in DCIS.HER2 status is a known risk factor for recurrence in
both invasive breast carcinoma and DCIS. Two recent
publications have shown an increased risk of non-
invasive recurrence in HER2+ tumours [8,17]. In the
study by Rakovitch et al., the combination of HER2+
and high proliferation conferred an even higher risk of
non-invasive recurrence and in the study by Kerlikowske
et al., the combination of HER2+, ER- and high prolif-
eration was associated with a six times increased risk
of non-invasive recurrence. Our data did go in the
same direction with a higher risk for local recurrence
in the HER2+/ER- subtype including both in situ and
invasive events and, a lower risk for any invasive re-
currence. Other biological markers have also been stud-
ied but there were no significant associations found
between a variety of biologic markers and the risk of re-
currence after a primary DCIS as reviewed by Lari and
Kuerer [18].
In this study we wanted to examine whether different
cut offs for Ki67 assessment could influence the prog-
nostic ability of the Luminal A and Luminal B/HER2-
Figure 1 Kaplan–Meier analyses of a) local recurrence, b) invasive or general recurrence and c) all events by DCIS molecular subtypes
by immunohistochemistry according to St Gallen criteria in 381 women with a primary DCIS.
Zhou et al. BMC Cancer 2013, 13:512 Page 6 of 9
http://www.biomedcentral.com/1471-2407/13/512
Figure 2 Kaplan–Meier analyses of a) local recurrence, b) invasive or general recurrence and c) all events by DCIS molecular subtypes
by immunohistochemistry according to St Gallen criteria in 300 women with a primary DCIS undergoing breast-conserving surgery (BCS).
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http://www.biomedcentral.com/1471-2407/13/512molecular subtypes. The St Gallen criteria use a cut off
at 14%. This cut off has been rejected by the IMPAKT
working group [19] and there are also difficulties in re-
producibility when scoring Ki67 [20]. By using different
cut offs, tumours from a number of women will poten-
tially change molecular subtype. In this cohort, only 10
women changed from Luminal B/HER2- to Luminal A
by raising the Ki67 cut off from 14% to 20%. No women
changed molecular subtype by lowering the cut off to
10%. If we had used yet another cut off, e.g., 30%, only
an additional three women would have changed from
Luminal B/HER2- to Luminal A. Altogether, we could
not see any influence on prognosis in any of our analyses
using the different Ki67 cut off levels.
If we compare the surrogate molecular subtypes using
the St Gallen criteria with subtypes using the Livasy
(Livasy [21]) classification, proliferation is the main dif-
ference. PR status is not used and EGFR + or CK5/6+ is
necessary for defining the basal like subtype in the
Livasy classification. E.g., of the 27 Triple Negative cases
by the St Gallen criteria, eight were unclassified accord-
ing to Livasy criteria as either EGFR or CK5/6 were
missing. And, of the 35 basal like cases by Livasy, three
were unclassified, 4 were Luminal A and one Luminal B/
HER2- using the St Gallen criteria due to PR status.
These circumstances make comparisons between studies
using different criteria difficult.
Conclusions
We could not find that the surrogate molecular subtyp-
ing proposed by the St Gallen international expert con-
sensus for invasive breast cancer, 2011, was a prognostic
useful tool in DCIS. We found a significantly higher risk
of developing a new breast cancer event after ten years
in the Triple Negative subtype but this was based on few
events. Our data, however not statistically significant,
did support newly published data indicating that HER2+
in itself is a risk factor for recurrence, but more specific-
ally, non-invasive recurrence and this need to be further
explore.
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